Intellia Therapeutics Inc (NASDAQ:NTLA) EVP Jose E. Rivera sold 624 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $35.00, for a total value of $21,840.00. Following the completion of the transaction, the executive vice president now directly owns 52,315 shares of the company’s stock, valued at $1,831,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Intellia Therapeutics stock opened at $32.34 on Friday. Intellia Therapeutics Inc has a twelve month low of $9.18 and a twelve month high of $35.54. The firm has a market capitalization of $1.91 billion, a PE ratio of -14.18 and a beta of 1.59. The firm’s 50-day moving average price is $26.13 and its 200 day moving average price is $21.52.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. Intellia Therapeutics had a negative return on equity of 40.57% and a negative net margin of 228.87%. The business had revenue of $22.22 million for the quarter, compared to the consensus estimate of $14.95 million. During the same quarter last year, the business posted ($0.49) earnings per share. The business’s quarterly revenue was up 109.2% compared to the same quarter last year. On average, equities analysts anticipate that Intellia Therapeutics Inc will post -2.36 EPS for the current fiscal year.

NTLA has been the subject of several recent research reports. The Goldman Sachs Group started coverage on shares of Intellia Therapeutics in a report on Friday, September 18th. They set a “buy” rating and a $33.00 target price for the company. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 16th. Wells Fargo & Company initiated coverage on shares of Intellia Therapeutics in a research note on Wednesday, October 14th. They set an “overweight” rating on the stock. Zacks Investment Research lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a report on Thursday, November 5th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $30.56.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. boosted its stake in Intellia Therapeutics by 11.4% during the first quarter. Invesco Ltd. now owns 19,922 shares of the company’s stock worth $244,000 after buying an additional 2,034 shares during the period. Advisor Group Holdings Inc. purchased a new stake in Intellia Therapeutics in the first quarter valued at approximately $168,000. State Street Corp lifted its stake in Intellia Therapeutics by 1.8% during the first quarter. State Street Corp now owns 1,724,683 shares of the company’s stock worth $21,093,000 after purchasing an additional 31,214 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Intellia Therapeutics by 577.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 73,353 shares of the company’s stock worth $1,542,000 after buying an additional 62,527 shares during the period. Finally, Valeo Financial Advisors LLC boosted its position in shares of Intellia Therapeutics by 1,078.0% during the second quarter. Valeo Financial Advisors LLC now owns 9,082 shares of the company’s stock worth $191,000 after buying an additional 8,311 shares during the period. 91.79% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B.

Further Reading: Insider Trading

Insider Buying and Selling by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.